UBS lowered the firm’s price target on Delek US (DK) to $13.25 from $21 and keeps a Neutral rating on the shares. The firm estimates a total EBITDA loss for Q1 of $0M vs. (23M) in Q4, with weaker refining earnings driving negative revisions vs. prior expectations, the analyst tells investors in a research note. UBS views Delek’s refining as challenged in the near-term, but sees the company growing its midstream business.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DK:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue